Skip to main content

Table 2 Preoperative patient baseline information

From: Prosthesis-patient mismatch after mitral valve replacement: a single-centered retrospective analysis in East China

preoperative information total
(n = 1067)
PPM group
(n = 189)
non-PPM group
(n = 878)
P value
Age, y 56(48–62) 63(55–67) 54(46–61) < 0.001
Male 379(35.5%) 89(47.1%) 290(33.0%) < 0.001
Height, cm 160.72 ± 7.82 163.26 ± 7.87 160.17 ± 7.71 < 0.001
Weight, kg 57.72 ± 10.33 62.42 ± 10.23 56.70 ± 10.07 < 0.001
BMI, kg/m2 22.29 ± 3.67 23.34 ± 2.86 22.07 ± 3.79 < 0.001
BSA, m2 1.57 ± 0.16 1.64 ± 0.17 1.55 ± 0.16 < 0.001
Smoking history 123(11.5%) 32(16.9%) 91(10.4%) 0.016
Diabetes 102(9.6%) 22(11.6%) 80(9.2%) NS
Hypertention 192(18.0%) 47(24.9%) 145(16.5%) 0.009
Cerebrovascular accident 34(3.2%) 6(3.2%) 28(3.2%) NS
Coronary heart disease 22(2.1%) 9(4.8%) 13(1.5%) 0.009
NYHA functional class (≥ III) 400(37.5%) 77(40.7%) 323(36.8%) NS
Atrial fibrillation 533(50.0%) 92(48.7%) 441(50.2%) NS
Previous cardiac surgery 54(5.1%) 8(4.2%) 46(5.2%) NS
Previous MI 1(0.1%) 0(0.0%) 1(0.1%) NS
Mitral stenosis 786(76.7%) 128(67.7%) 658(74.9%) 0.036
MR (moderate to severe) 470(44.0%) 88(46.5%) 382(43.5%) NS
LVEF 62.11 ± 8.48 62.23 ± 8.95 62.09 ± 8.38 NS
LVdD, mm 50(45–56) 51(46–58) 50(45–56) NS
LAD, mm 51.36 ± 12.04 51.36 ± 11.93 51.36 ± 12.07 NS
Emergency surgery 2(0.2%) 0(0.0%) 0(0.0%) NS
Aspirin within 5 days 29(2.7%) 9(4.8%) 20(2.3%) NS
Clopidogrel within 5 days 19(1.8%) 6(3.2%) 13(1.5%) NS
  1. BMI body mass index, BSA body surface area, NYHA New York Heart Association, MI myocardial infarction, MR mitral valve regurgitation, LVEF left ventricular ejection fraction, LVdD left ventricular diastolic diameter, LAD left atrial diameter, NS not significant